Investors & Media Press Releases

Axovant Sciences to Present at Upcoming Investor Conferences


HAMILTON, Bermuda, May 9, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at two investor conferences:

  • May 23 at 8:30 a.m. EDT at the UBS Global Healthcare Conference
  • June 7 at 2:00 p.m. EDT at the Jefferies Healthcare Conference

A simultaneous webcast can be accessed by visiting the Investors section of and selecting Events and Presentations. A replay will be available for 30 days following each conference.

About Axovant 
Axovant Sciences Ltd. is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral components of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of the disease.

To view the original version on PR Newswire, visit:

SOURCE Axovant Sciences Ltd.

Jonathan Neely
Head, Investor Relations and Corporate Communications
Axovant Sciences, Inc.
(212) 634-9744